These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 22329724

  • 1. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
    Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC.
    Pharmacogenomics; 2012 Mar; 13(4):407-18. PubMed ID: 22329724
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
    Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT.
    Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
    [Abstract] [Full Text] [Related]

  • 5. The future of warfarin pharmacogenetics in under-represented minority groups.
    Cavallari LH, Perera MA.
    Future Cardiol; 2012 Jul; 8(4):563-76. PubMed ID: 22871196
    [Abstract] [Full Text] [Related]

  • 6. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.
    Blood Cells Mol Dis; 2009 Jul; 43(1):119-28. PubMed ID: 19297219
    [Abstract] [Full Text] [Related]

  • 7. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS.
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [Abstract] [Full Text] [Related]

  • 11. Genetic and clinical predictors of warfarin dose requirements in African Americans.
    Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA.
    Clin Pharmacol Ther; 2010 Apr; 87(4):459-64. PubMed ID: 20072124
    [Abstract] [Full Text] [Related]

  • 12. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE.
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [Abstract] [Full Text] [Related]

  • 13. Race influences warfarin dose changes associated with genetic factors.
    Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK, Beasley TM.
    Blood; 2015 Jul 23; 126(4):539-45. PubMed ID: 26024874
    [Abstract] [Full Text] [Related]

  • 14. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
    Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ.
    Clin Pharmacol Ther; 2011 Mar 23; 89(3):408-15. PubMed ID: 21270790
    [Abstract] [Full Text] [Related]

  • 15. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.
    Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH.
    Br J Clin Pharmacol; 2011 Sep 23; 72(3):442-50. PubMed ID: 21320153
    [Abstract] [Full Text] [Related]

  • 16. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.
    J Thromb Thrombolysis; 2006 Dec 23; 22(3):191-7. PubMed ID: 17111199
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.
    Scott SA, Patel M, Martis S, Lubitz SA, van der Zee S, Yoo C, Edelmann L, Halperin JL, Desnick RJ.
    Pharmacogenomics; 2012 Feb 23; 13(3):297-307. PubMed ID: 22188360
    [Abstract] [Full Text] [Related]

  • 19. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El Shafey M, Ali SS, Mohamed ME, Langaee T, Johnson JA.
    Pharmacogenet Genomics; 2011 Mar 23; 21(3):130-5. PubMed ID: 21228733
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.